Goldman Sachs initiates Stoke Therapeutics stock with buy rating on Dravet therapy potential

Goldman Sachs initiates Stoke Therapeutics stock with buy rating on Dravet therapy potential

Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.